Basic Information
Kirsty (previously Kixelle)
Regulatory Information
EMEA/H/C/004965
February 5, 2021
December 10, 2020
4
September 27, 2023
Company Information
Ireland
Unit 35/36 Grange Parade, Baldoyle Industrial Estate Dublin 13 DUBLIN D13 R20R
Biosimilar Collaborations Ireland Ltd.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Overview Summary
Kirsty is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Kirsty is a ‘biosimilar medicine’. This means that Kirsty is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Kirsty is NovoRapid. For more information on biosimilar medicines, see [here](/en/outdated-human-medicines-regulatory-information). Kirsty contains the active substance insulin aspart.